RxDoctor Payments Data

Akshay Patel, MD

Internal Medicine · Toms River, NJNPI 1396737581

Payments from drug & device makers

$27,454in general payments, 2019–2025

Across 64 payments — averaging $428.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$27K
  • Exact Sciences$139
  • AstraZeneca$125
  • Davol Inc.$121
  • Boston Scientific$83
  • Nestle Healthcare Nutrition Inc.$69
  • plus $229 from 10 others

What the payments were for

  • Consulting fees$12,25045%
  • Speaking & faculty fees$11,50042%
  • Travel & lodging$2,1088%
  • Food & beverage$1,5966%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,454 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$263,532
Medicare patients
778
Services billed
3,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate59$288,923
EliquisApixaban548$232,777
Invega SustennaPaliperidone Palmitate29$108,719
XareltoRivaroxaban204$90,444
JanuviaSitagliptin Phosphate204$77,189
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$54,961
Dupixent PenDupilumab13$48,676
JardianceEmpagliflozin108$42,766
VivitrolNaltrexone Microspheres23$41,723
TrulicityDulaglutide47$41,524
OzempicSemaglutide33$37,219
VraylarCariprazine Hcl43$35,521
NuedextaDextromethorphan Hbr/Quinidine32$30,285
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$28,804
MyrbetriqMirabegron93$28,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$41$199,163233 claims
MerckJanuvia, Janumet$18$100,697243 claims
Lilly USA, LLCTrulicity, Mounjaro$30$54,47162 claims
AbbVieVraylar, Creon$14$51,80377 claims
Novo NordiskOzempic$43$37,21933 claims
AstraZenecaFarxiga$125$14,70049 claims
NovartisEntresto$13$13,14624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →